Clearside Biomedical Inc ((CLSD)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Clearside Biomedical Inc. recently completed a clinical study titled ‘ODYSSEY: A Phase 2b Study of Suprachoroidally Administered CLS-AX in Participants With Neovascular Age-Related Macular Degeneration.’ The study aimed to evaluate the safety and efficacy of CLS-AX, a new treatment for neovascular age-related macular degeneration (AMD), a leading cause of vision loss. This study is significant as it explores an alternative to the current standard anti-VEGF therapies.
The intervention being tested is CLS-AX, administered via suprachoroidal injection. This method is designed to deliver the drug directly to the back of the eye, potentially offering a more targeted treatment for AMD compared to traditional methods.
The study was interventional, randomized, and double-masked, with participants assigned to either the experimental group receiving CLS-AX or the active comparator group receiving aflibercept. The primary purpose was treatment, with a focus on assessing the drug’s safety and efficacy over a 36-week period.
The study began on May 31, 2023, and was completed with the last update submitted on July 24, 2025. These dates are crucial as they mark the progression and completion of the study, providing a timeline for investors to gauge the development stage of CLS-AX.
The completion of this study could positively influence Clearside Biomedical’s stock performance, as successful results may lead to a new treatment option in the AMD market. This could shift investor sentiment favorably, especially if CLS-AX proves to be a viable competitor to existing therapies like aflibercept.
The study is now completed, with further details available on the ClinicalTrials portal.